Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Liver Cancer
LAMH receives Chinese approval for blood test designed to accelerate liver cancer diagnosis
The test was based on the multianalyte blood test HelioLiver, developed by Helio Genomics, and adapted for the genetics of the Asia-Pacific population, resulting in a product that could help address a major healthcare challenge in China.
July 5, 2023
Gene mutations linked to drug-resistant liver cancer
Certain gene mutations could help physicians predict which hepatocellular carcinoma patients are most likely to develop drug resistance to lenvatinib.
June 26, 2023
Johns Hopkins cell-free DNA blood test detects 80% of liver cancers in study
The researchers believe there is potential to leverage the technology to develop a commercial blood test to detect hepatocellular cancer with higher accuracy than current tests.
November 18, 2022
Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform
Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.
October 28, 2022
Biomarker assay may speed primary liver cancer detection
While EVs are released by normal cells, they are released to a greater extent by tumor cells and cells within a tumor microenvironment. Investigators at the University of California at Los Angeles (UCLA) and collaborators elsewhere have developed a streamlined surface protein assay (HCC EV SPA) capable of analyzing and quantifying eight subpopulations of HCC EVs.
August 15, 2022
Helio Genomics obtains CPT code for liver cancer test
When it takes effect on October 1, the new CPT PLA code will provide a reimbursement pathway to enable increased access to HelioLiver, according to the vendors.
July 4, 2022
Helio publishes study of HelioLiver cancer test
In a prospective phase II study, HelioLiver demonstrated high specificity (91%) and high sensitivity (76%) in detecting early-stage (stage I and II) HCC. In addition, it significantly outperformed other clinically available detection tools such as serum alpha-fetoprotein (AFP) (57%), GALAD (gender, age, Lens culinaris agglutinin-reactive AFP, and des-gamma-carboxy prothrombin [DCP]) scores (65%), and ultrasound (47%) (Hepatology Communications, March 3, 2022).
March 9, 2022
Fujifilm, Helio partner on blood assay for detecting liver cancer
Helio Health's DNA methylation and biomarker-based blood test technology, called the HelioLiver test, will leverage Fujifilm's 510(k)-cleared, microfluidic-based clinical immunoanalyzer for IVD use, according to the companies.
May 12, 2021
Liver cancer diagnostic test offers promise of early detection
The platform is called EV Click Chips, and the hope is that it will enable more effective purification of extracellular vesicles in blood from people with hepatocellular carcinoma. Researchers from the University of California, Los Angeles (UCLA) Jonsson Comprehensive Cancer Center have received a $2.97Â million grant from the U.S. National Cancer Institute (NCI) to develop the technology further.
August 4, 2020
Blood test identifies patients at risk for liver cancer
The test analyzes patients' previous viral exposure to accurately predict whether they might develop hepatocellular carcinoma (HCC). It was created by researchers from the U.S. National Institutes of Health and several academic centers to help improve liver cancer screening and early detection.
June 11, 2020
Page 1 of 1
